A decade of studies has underlined the complexity of the genetic events that characterise the genomic landscapes of common forms of human cancer, including gliomas. While a few cancer genes are mutated at high frequencies (>20%), the greatest number of cancer genes in most patients appear at intermediate frequencies (2–20%) or lower. Strikingly, the functional significance of the vast majority of these alterations remains elusive. A current high priority in glioma research is to functionally validate candidate genetic alterations in order to identify those that are significant for cancer progression and treatment response
In our laboratory, we use a combination of genomic analyses, mouse models, and primary tumour cell cultures, with the main goal of identifying the molecular mechanisms that could provide the basis for novel treatments for glioma patients.